Toxicity review of CBD for use as a novel ingredient in e-liquids

Client

A manufacturer of e-cigarettes.

Background

The client is interested in introducing CBD (cannabidiol), the major non-psychoactive component of cannabis, as an ingredient to its e-liquids. The e-liquids are intended to be used in vaping products, which could potentially expose the lungs of consumers to this cannabinoid on a daily basis for many years. Therefore, the client has deemed it necessary to conduct a toxicological assessment on CBD and its isomers.

Project goals

To produce a toxicity review that primarily focuses on, where available, good-quality in vivo data and the inhalation route of exposure for CBD and its isomers, whilst also considering the potential impurities that may be present in CBD products.

Approach

Bibra conducted a wide-ranging search for substance-specific toxicity data and subsequently collected and assessed the relevant expert group reports, reviews and primary literature on CBD and its isomers. The key data, derived primarily from high-quality studies with the most relevance to repeated and prolonged exposure by inhalation, were highlighted and summarised for an array of toxicological endpoints.

Project outcome

Bibra successfully carried out a toxicological assessment of CBD and its isomers, whilst also identifying the possible impurities that may be present in CBD products. Additionally, the endpoints of toxicological concern (including evidence of increased liver enzymes in clinical trials, and of potential genotoxicity and reproductive/developmental toxicity in laboratory animals) or those that lacked information were identified. Future, opportunities for further investigation were also suggested.

Bibra project team

Richard Young
Pete Watts

 

E-cigarettes More recent work Info about us Meet our team